“Welcome to Early stages of Parkinson’s disease”
Primary cortical neuron with staining for MAP2, TGN-46 and DAPI.
Primary cortical neuron with staining for PPP2CA and LRRK2.
CRISPR/Cas9 technology used in the lab to silence or activate transcription in human cells: dCas9-mediated transcriptional modulation of phosphatases.
(A) dCas9 fused to effector domains can serve as an RNA-guided DNA-binding protein to target any protein to any DNA sequence. The effectors used with the catalytically inactive Cas9 (dCas9) are KRAB fusion protein to repress (CRISPRi) or the VP64 fusion protein to activate (CRISPRa) expression has shown on the picture.
(B) Stable suppression and overexpression of PPP1R1B by dCas9-KRAB or dCas9-VP64 in SH-SY5Y cells respectively. Cells stably expressing dCas9-KRAB or VP64 were infected with lentivirus constructs expressing a negative control sgRNA or two different sgRNAs targeting PPP1R1B.
MARCHAND Antoine (D1)
LRRK2 and deficits of membrane trafficking in Parkinson’s disease.
SARCHIOSE Alessia (D1)
Defect of membrane trafficking in Parkinson’s disease: role of Alpha-synuclein.
CUVELIER Élodie (D3)
Modulation of glucocerebrosidase activity in a transgenic mouse model overexpressing human alpha-synuclein.
DROUYER Matthieu (D3)
Validation of protein phosphatases that regulate the LRRK2 phosphorylation cycle.
SEKFALI Manelle, Master 2
LEGHAY Coline, PhD, Ingénieur de Recherche
SIBRAN Willian, Ingénieur d’études
VANDEWYNCKEL Laurine, Assistant Ingénieur
PHONGPHAISANE Melody, Technicienne
CARRIE Hélène, PhD, PharmD, ATER